RT Journal Article
SR Electronic
T1 Association of machine learning-derived measures of body fat distribution in >40,000 individuals with cardiometabolic diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.07.21256854
DO 10.1101/2021.05.07.21256854
A1 Saaket Agrawal
A1 Marcus D. R. Klarqvist
A1 Nathaniel Diamant
A1 Patrick T. Ellinor
A1 Nehal N. Mehta
A1 Anthony Philippakis
A1 Kenney Ng
A1 Puneet Batra
A1 Amit V. Khera
YR 2021
UL http://medrxiv.org/content/early/2021/05/10/2021.05.07.21256854.abstract
AB Background Obesity is defined based on body-mass index (BMI), a proxy for overall adiposity. However, for any given BMI, individuals vary substantially in fat distribution. The clinical implications of this variability are not fully understood.Methods We studied MRI imaging data of 40,032 UK Biobank participants. Using previously quantified visceral (VAT), abdominal subcutaneous (ASAT), and gluteofemoral (GFAT) adipose tissue volume in up to 9,041 to train convolutional neural networks, we quantified these depots in the remainder of the participants. We derived new metrics for each adipose depot – fully independent of BMI – by quantifying deviation from values predicted by BMI (e.g. VAT adjusted for BMI, VATadjBMI) and determined associations with cardiometabolic diseases.Results Machine learning models based on two-dimensional projection images enabled near-perfect estimation of VAT, ASAT, and GFAT, with r2 in a holdout testing dataset >0.97 for each. Using the newly derived measures of local adiposity – residualized based on BMI – we note marked heterogeneity in associations with cardiometabolic diseases. Taking presence of type 2 diabetes as an example, VATadjBMI was associated with significantly increased risk (odds ratio per standard deviation increase (OR/SD) 1.49; 95%CI: 1.43-1.55), while ASATadjBMI was largely neutral (OR/SD 1.08; 95%CI: 1.03-1.14) and GFATadjBMI conferred protection (OR/SD 0.75; 95%CI: 0.71-0.79). Similar patterns were observed for coronary artery disease.Conclusions For any given BMI, measures of local adiposity have variable and divergent associations with cardiometabolic diseases.Competing Interest StatementM.D.R.K., N.D., A.P, and P.B. are supported by grants from Bayer AG applying machine learning in cardiovascular disease. P.T.E. receives sponsored research support from Bayer AG and IBM and has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics. A.P. is also employed as a Venture Partner at GV and consulted for Novartis; and has received funding from Intel, Verily and MSFT. K.N. is an employee of IBM Research. P.B serves as a consultant for Novartis. A.V.K. has served as a scientific advisor to Sanofi, Medicines Company, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Verve Therapeutics, Amgen, Color, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from the Novartis Institute for Biomedical Research.Funding StatementThis work was supported by the Sarnoff Cardiovascular Research Foundation Fellowship (to S.A.), grant 1K08HG010155 (to A.V.K.) from the National Human Genome Research Institute, a Hassenfeld Scholar Award from Massachusetts General Hospital (to A.V.K.), a Merkin Institute Fellowship from the Broad Institute of MIT and Harvard (to A.V.K.), and a sponsored research agreement from IBM Research to the Broad Institute of MIT and Harvard (P.T.E., A.P., P.B., A.V.K.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC), which covers the UK.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode used to ingest whole-body Dixon MRI images from UK Biobank participants is made available at https://github.com/broadinstitute/ml4h/tree/master/ml4h/applications/ingest under an open-source BSD license. At the time of publication, new UK Biobank measures derived in this manuscript will be returned to the UK Biobank for other investigators to download.